Zaloguj Zarejestruj się zadarmo

180 Life Sciences organizacji Wskaźnik krótkiej sprzedaży

Jaka jest wartość Wskaźnik krótkiej sprzedaży organizacji 180 Life Sciences?

Wartość Wskaźnik krótkiej sprzedaży organizacji 180 Life Sciences Corp. to 6.78

Jaka jest definicja Wskaźnik krótkiej sprzedaży?



Wskaźnik krótkiej sprzedaży (Short ratio) to liczba akcji sprzedanych na krótko podzielona przez średnią wartość dzienną.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Wskaźnik krótkiej sprzedaży firm w Health Care sektor na NASDAQ w porównaniu do 180 Life Sciences

Czym się zajmuję organizacja 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Firmy z wskaźnik krótkiej sprzedaży podobne do 180 Life Sciences